Articles tagged with Plasmodium
Researchers found that high fever can activate the Heat Shock Response in malaria parasites, making them non-infectious. This protective mechanism may help prevent disease transmission from humans to mosquitoes.
A PSU-led research team has developed a novel chemical compound, T111, that shows promise for treating and preventing malaria. The compound targets all three major life-cycle stages of the malaria parasite, making it a strong candidate for a single-encounter radical cure.
Researchers found that methylene blue can reverse brain damage caused by cerebral malaria and identified a nine-gene blood signature to diagnose the disease. The study's findings offer new clues on immune processes involved in brain injury and suggest potential for early intervention and clearer treatment decisions.
Researchers developed a new method to identify functional plasma antibodies against malaria using mass spectrometry sequencing, providing valuable insight into protective antibody responses. The study identified a broadly neutralizing antibody with broad inhibitory activity against diverse PfEMP1 variants.
Researchers discovered a potential vulnerability in P. falciparum by inducing protein aggregation, leading to reduced parasite growth. The study may lead to novel antimalarial strategies targeting the parasite's internal protein folding machinery.
Researchers have discovered a family of exported proteins in the malaria-causing parasite Plasmodium falciparum that may hold promise for identifying new drugs. The proteins, known as FIKK kinases, were found to be necessary for the parasite's survival and likely played a key role in its evolution to infect humans.
Scientists have mapped the global repertoire of genes that determine the male or female sexual fates in Plasmodium falciparum malaria parasites. This study reveals key regulators of gene expression during development and identifies novel candidate 'driver' genes, shedding light on the complex biology of malaria transmission.
A recent study has identified a key component of the malaria parasite's invasion mechanism, revealing that it binds to a specific sugar called sialic acid on red blood cell surfaces. This discovery provides new insights into the parasite's adaptation to humans and offers potential targets for vaccine and drug development.
Scientists have identified specific long noncoding RNAs that regulate gene expression and life cycle progression of the deadly Plasmodium falciparum malaria parasite. The discovery could lead to new therapeutic strategies against malaria.
Researchers tested an automated microscope combined with AI software to diagnose malaria in blood samples. The system achieved 88% accuracy, comparable to expert microscopists, and has potential benefits including reducing workload and increasing patient load.
A recent study found that malaria control programs in Amazonian Peru reduced the disease by 78% but saw a rebound when funding was cut, driven by climate change. Climate change has exacerbated malaria transmission, with rising temperatures and intense rainfalls contributing to the resurgence of the mosquito-borne disease.
Researchers created an atlas of the malaria infection by Plasmodium parasites in the liver, revealing differences in infected cell localization and immune response. The study's findings hold promise for developing treatments targeting the asymptomatic liver stage of the disease.
Researchers have discovered a protein that plays a key role in the malaria parasite, leading to a potential new way to fight the disease. Deactivating this protein reduces the growth of the parasite by over 75%, making it a promising target for treatment development.
Researchers from Ethiopia and Germany identified a traditional African medicinal plant that alleviates malaria symptoms in infected mice. The plant extract's active compound, anemonin, shows promise in treating the disease.
Chronic P. vivax infections cause significant damage to kidneys, brain, and circulatory system, affecting impoverished communities. The parasite can hide at low levels, making diagnosis difficult and treatment efforts challenging.
The collection discusses the epidemiology of P. vivax, highlighting its burden on young children in remote areas with poor healthcare infrastructure. Effective drugs are available but come with limitations, prompting a radical cure approach to eliminate the parasite and prevent relapses.
A new CRISPR-based assay detects all four major malaria-causing Plasmodium species with high sensitivity and specificity, providing a viable solution to diagnose asymptomatic carriers. The SHERLOCK system enables rapid testing in just 60 minutes, surpassing WHO requirements for low parasite density detection.
High-resolution maps show progress in defeating malaria, but also highlight areas of stagnation and increased burden, particularly in Venezuela and sub-Saharan Africa. The research emphasizes the need for targeted interventions and sustained funding to overcome obstacles to eradication.
Researchers developed a modified CRISPR/Cas9 system to efficiently edit the malarial parasite Plasmodium falciparum's gene expression. By altering histone acetylation near invasion-related genes, they increased or decreased erythrocyte invasion efficiency.
A new study published by Insilico Medicine using artificial intelligence has identified potential FP2 blockers, which could lead to the development of new antimalarial drugs. The research provides insights into the properties of E64 approaches and their interaction with falcipain-2, a key target for malaria treatment.
The study identifies 14 common chemicals that can impact assay conclusions without compromising plasmodium growth and proliferation. The team estimates maximum allowable concentrations compatible with the assay, ensuring normal parasite survival and proliferation.
A study comparing ape and human P. vivax genomes reveals nearly identical DNA sequences, but with key differences in genetic diversity and binding proteins. The findings suggest an evolutionary bottleneck where the parasite passed from apes to humans in Africa, then spread globally.
A team of malaria experts has published results supporting the need for a radical cure strategy to tackle Plasmodium vivax, a debilitating form of malaria. The study found that chloroquine is currently given in lower doses than recommended, leading to higher rates of treatment failure.
Researchers have created the most comprehensive tree of life for malaria parasites, revealing diverse evolutionary lineages and proposing that some species should be renamed. The study included DNA sequence data from over 20 genes and sampled 58 malaria species across eight genera, correcting for biased DNA ratios.
A study revealed that Plasmodium falciparum emerged as a human-specific parasite species around 3,000 to 4,000 years ago. The researchers sequenced the genomes of all known malaria parasites and discovered a chain of events leading to its emergence.
Researchers found that malaria-carrying parasites, particularly Plasmodium, are more widespread due to their ability to infect multiple bird species. The study's findings suggest that geography and host evolutionary relationships play significant roles in shaping parasite diversity and distribution patterns.
A recent study has identified a fatty molecule in human blood that controls the malaria parasite's decision to switch from replicating in humans to transmitting to mosquitoes. This discovery improves understanding of a critical stage in the Plasmodium life cycle and may lead to new strategies for controlling and treating malaria.
The genomes of Plasmodium malariae and Plasmodium ovale parasites have been sequenced, revealing genes that could be involved in human infection and immune evasion. These findings may lead to the development of improved diagnostic tools and vaccines against these less common but still deadly malaria species.
Researchers at Institut Pasteur have created a live, genetically attenuated vaccine for Plasmodium that triggers a potent immune response and provides long-term protection against malaria. The vaccine uses a mutated gene that boosts the production of an IL-6 cytokine, resulting in a strong cellular and humoral response.
The study reveals that Plasmodium falciparum, the deadliest malaria parasite, has a limited genetic diversity compared to its chimpanzee and gorilla cousins. The team found an expansion of a multi-gene family in Laverania parasites that helps them evade host immune cells and clear the spleen, contributing to severe malaria pathology.
Researchers from University of Nottingham uncover cyclin's crucial role in malaria parasite development within mosquitoes and mammal hosts. The study identifies three types of cyclin, shedding light on the disease's complex life cycle.
Researchers from Karolinska Institutet identified the key role of RIFIN protein in protecting blood type O individuals from severe malaria. The protein binds strongly to A blood cells but weakly to O, explaining why O individuals are less susceptible to the disease.
A new study led by University of Maryland School Medicine researcher Joana C. Silva found that five common Plasmodium species have not changed which animals they infect for at least 3 million years. This suggests that host switching by malaria-causing parasites is not a common event on an evolutionary time scale.
A study by University of Veterinary Medicine -- Vienna researchers has identified avian malaria in 15% of examined wild birds in Austria, showing that native bird populations are susceptible to the disease. Three different Plasmodium species were also found, with one new species still requiring analysis and classification.
MIT researchers have developed a new genome-editing technique using CRISPR to disrupt malaria genes with up to 100% success rate in weeks. This approach could accelerate the identification of novel therapeutic targets for malaria drugs and vaccines.
Scientists investigated the malaria pathogen's cellular skeleton using high-resolution structural biology methods. They discovered two versions of actin protein with different structures and behaviors, which may contribute to designing tailored anti-malarial medication.
Researchers at the University of Geneva have discovered a new class of molecules that target the heat shock protein 90 in Plasmodium falciparum, a key factor in malaria resistance. The study reveals five candidate molecules toxic to the parasite but not human red blood cells.
UC Riverside researchers have discovered low levels of DNA methylation in Plasmodium's genome, which may be critical to the survival of the parasite. This finding could lead to the development of a new drug to kill the deadly malaria parasite.
Researchers have identified phosphatidylinositol 4-kinase (PI4K) as a potential malaria drug target, essential throughout the Plasmodium life cycle. Imidazopyrazines inhibit PI4K activity, blocking parasite development in both liver and bloodstream stages.
Researchers discovered four genera of haemosporidian parasites in West African bats, closely related to the malaria pathogen Plasmodium. The study highlights the complex relationship between bats and pathogens, with potential implications for understanding human malaria evolution and developing new vaccines.
A team led by UC Riverside's Karine Le Roch will study the 3-D structure of the malaria parasite's genome during its erythrocytic cycle, which could lead to insights into how parasite genes are regulated. This information is crucial for designing new drugs and novel lines of defense against malaria.
Hebrew University researchers discovered how Plasmodium falciparum hides its genes from the immune system by using an insulator-like DNA sequence. This breakthrough could lead to strategies to disrupt this ability and prevent malaria deaths, mainly among pregnant women and children.
Researchers have discovered a new potential treatment for malaria that rapidly kills the blood-borne Plasmodium parasites. The molecules identified can target all stages of the parasite's life cycle, offering hope for an effective cure within ten years.
Researchers developed a new class of compounds that block malaria transmission from humans to mosquitoes by inhibiting bumped kinase I. This approach represents a new strategy for controlling malaria spread. The study's preclinical data in mice suggests the inhibitors are safe and well-tolerated.
Researchers compared 50 antimalarials against liver, sexual blood, and mosquito stages of human and nonhuman parasite species. The study provides a guide to help researchers identify promising antimalarial drugs for future treatments.
Researchers at Washington University have characterized a protein crucial to the life of the malaria parasite, Plasmodium falciparum. The enzyme, phosphoethanolamine methyltransferase (PMT), is an ideal target for new antimalarial drugs due to its unique characteristics and lack of homologues in humans.
Researchers at Stanford and UCSF have developed a novel method to grow large volumes of modified malaria parasites that no longer cause the disease, revealing how the parasite's survival depends on isopentenyl pyrophosphate. This breakthrough could speed up drug development and provide a basis for an effective vaccine against malaria.
Researchers focus on disrupting FLVCR protein in mosquitoes to block Plasmodium transmission, a crucial step in preventing malaria spread. By targeting this protein, they hope to develop a vaccine to stimulate an immune response and prevent the disease.
Researchers have discovered a novel compound, spiroindolone NITD609, effective against both strains of the malaria parasite and shows pharmacological properties compatible with a once-daily dosing regimen.
Researchers successfully engineer mosquitoes immune to malaria parasite, rendering them ineffective vectors for human infection. The breakthrough has significant implications for global health, with an estimated 1 million fatalities annually due to the disease.
A study published in PLOS Medicine estimates that there were approximately 451 million clinical cases of Plasmodium falciparum malaria worldwide in 2007. The majority of this burden was attributed to India, Nigeria, the Democratic Republic of Congo, and Myanmar. These findings highlight the need for improved diagnosis and surveillance ...
A UCR researcher has identified a mechanism by which the malaria parasite replicates in human red blood cells, intensifying its infectious cycle. The 'histone crash' process involves the massive breakdown of histones, allowing for rapid gene transcription and multiplication.
A study by Dr. Gregory A. Elder found that presenilin-1 plays a role in the vascular pathology associated with Alzheimer disease, while another study discovered that osteopontin contributes to allergic contact dermatitis. Weakened Plasmodium parasites also elicit a protective immune response.
Scientists are developing genetically modified mosquitoes resistant to malaria and creating a rapid saliva-based diagnostic test. Researchers are also exploring ways to manipulate bacteria found in mosquito guts to kill the parasite without harming the insect.
Researchers identified a molecular pathway that triggers an immune response in multiple mosquito species, blocking the development of malaria-causing parasites. By activating transcription factor Rel 2, mosquitoes were able to mount an efficient defense against Plasmodium falciparum.
Research identifies PKG as essential molecule for malaria parasite's reproductive cycle. The protein is necessary for 'rounding up' transformation, allowing fertilization to occur.
Researchers have developed a genetic identity card for Plasmodium falciparum populations, revealing high genetic diversity and inbreeding rates. The study's findings can help predict changes in genes involved in drug resistance, enabling targeted therapies to minimize resistance development.
Researchers identified the AgDscam gene, essential for recognizing a broad range of pathogens in mosquitoes. Silencing this gene increases susceptibility to bacterial infections and malaria, highlighting its potential as a target for novel control methods.
Researchers examined the mosquito immune system and found that it employs similar factors to defend against different Plasmodium species. Boosting the mosquito's capacity to fight malaria parasites could be achieved through exposure to certain microbes or compounds.
Researchers developed a new method to identify novel drug targets for fighting malaria by comparing protein interactions in Plasmodium falciparum with other organisms. This approach could lead to the development of antimalarial drugs that exploit unique differences in protein wiring.